Physician

Kompal Parmar, M.D.

According to 2025 Medicare claims, Kompal Parmar, M.D. (NPI: 1710270988) practices family practice in the Lubbock, TX market, with the plurality of this provider's patient population coming from Lubbock, TX. This provider's primary affiliated billing organization is COVENANT MEDICAL GROUP (NPI: 1376598904; TIN: 752745546) and primary practice location at 79424-5781. Parmar is affiliated with the Covenant ACO, Inc. (ACO ID: A2021) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Parmar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,119 traditional Medicare patients, billed 9,722 HCPCS/CPT codes, and received $235,010 in Medicare payments. The top billing code was 84443 (Blood test, thyroid stimulating hormone (tsh)). Part D data shows 14,683 prescription claims across 835 beneficiaries totaling $1,334,706 in drug costs, led by Mounjaro (Tirzepatide). DME data shows 296 claims. Open Payments data shows 94 records totaling $1,695. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $37,139 to $235,010. Similarly, Part D prescription costs have moved sharply higher in recent years, from $171,519 to $1,334,706. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,281 to $41,761.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	300	3,319	$37,139
2016	340	2,406	$54,596
2017	384	2,233	$82,974
2018	471	3,645	$120,924
2019	545	6,977	$153,192
2020	459	5,481	$140,142
2021	825	6,920	$171,799
2022	1,000	8,952	$179,174
2023	988	9,930	$198,803
2024	1,119	9,722	$235,010

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	324	2,825	$171,519
2016	391	4,241	$236,701
2017	447	4,400	$293,212
2018	573	6,139	$428,755
2019	683	9,511	$779,339
2020	626	10,027	$812,332
2021	634	10,874	$880,346
2022	733	11,735	$936,057
2023	774	13,558	$1,259,387
2024	835	14,683	$1,334,706

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	41	$580
2016	N/R	181	$6,492
2017	13	159	$4,836
2018	33	153	$3,336
2019	40	261	$7,986
2020	68	438	$18,512
2021	39	397	$16,530
2022	23	309	$19,140
2023	23	377	$29,025
2024	25	296	$22,400

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
84443	Blood test, thyroid stimulating hormone (tsh)	384	486	$16
80061	Blood test, lipids (cholesterol and triglycerides)	376	450	$13
80053	Blood test, comprehensive group of blood chemicals	466	608	$10
36415	Insertion of needle into vein for collection of blood sample	509	748	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	475	623	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Mounjaro	Tirzepatide	153	5,050	$186,153
Ozempic	Semaglutide	119	4,106	$131,328
Jardiance	Empagliflozin	85	5,056	$97,325
Januvia	Sitagliptin Phosphate	45	2,986	$52,931
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	73	2,540	$52,473

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	26	$9,850
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	34	$3,297
A4407	Ostomy skin barrier, with flange (solid, flexible, or accordion), extended wear, with built-in convexity, 4 x 4 inches or smaller, each	N	N/R	12	$2,199
A4419	Ostomy pouch, closed; for use on barrier with non-locking flange, with filter (2 piece), each	N	N/R	12	$1,326
K0001	Standard wheelchair	Y	N/R	40	$831

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	94	$1,695	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kompal Parmar, M.D.?

Tedicare shows public-source Medicare data for Kompal Parmar, M.D. (NPI 1710270988), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kompal Parmar, M.D. have ACO affiliation data?

Kompal Parmar, M.D. is shown with ACO affiliation data for Covenant ACO, Inc. (MSSP, ACO ID A2021) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Kompal Parmar, M.D.?

Kompal Parmar, M.D. is linked to COVENANT MEDICAL GROUP (billing NPI 1376598904) in the available physician profile data.

Does Kompal Parmar, M.D. have Open Payments data?

Kompal Parmar, M.D. has 94 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.